Dietary Guidance for Patients with Inflammatory Bowel Disease
Recommendations
Fruit and Vegetables
In CD, it is prudent to recommend moderate to high consumption of fruits and vegetables.
(L)In patients with symptomatic or significant fibrostricturing disease, insoluble fiber intake should be restricted.
(VL)In UC, there is insufficient evidence to recommend any specific change or restriction in intake of fruit and vegetables.
(VL)Refined Sugar and Carbohydrates
In CD, there is insufficient evidence to recommend any specific change of intake of complex carbohydrates or refined sugars and fructose.
(L)It may be prudent to use a low FODMAP diet for patients with persistent symptoms despite resolution of inflammation and absence of strictures.
(L)In UC, there is insufficient evidence to recommend any specific change of intake of complex carbohydrates or refined sugars and fructose.
(VL)It may be prudent to use a low FODMAP diet for patients with persistent symptoms despite resolution of inflammation.
(L)Wheat and Gluten
In CD, there is insufficient evidence to recommend restriction of wheat and gluten.
(L)In UC, there is insufficient evidence to recommend restriction of wheat and gluten.
(L)Red Meat, Processed Meat, Poultry, and Eggs
In CD, there is evidence that it is unnecessary to restrict moderate consumption of unprocessed red meat, lean chicken meat (breast of chicken), and eggs.
(H)In UC, it is prudent to reduce intake of red and processed meat.
(L)Dairy
Consensus was not obtained for CD or UC for pasteurized dairy products. Consensus was obtained that unpasteurized dairy products should not be consumed..
()Fat
In CD, it is prudent to reduce exposure to saturated fats
(L)and avoid trans fat.
In UC, it is prudent to reduce consumption of myristic acid (palm oil, coconut oil, dairy fats).
(L)It is prudent to increase dietary consumption of omega-3 fatty acids (DHA and EPA) from marine fish,
(L)but not from supplements.
It is prudent to avoid trans fat.
(VL)Alcohol
In CD, there is insufficient evidence to recommend changes in low-level alcohol consumption.
(L)In UC, there is insufficient evidence to recommend changes in low-level alcohol consumption.
(L)Maltodextrin and Artificial Sweeteners
In CD, it may be prudent to limit intake of maltodextrin-containing foods and artificial sweeteners.
(VL)In UC, it may be prudent to limit intake of maltodextrin-containing foods and artificial sweeteners.
(VL)Emulsifiers and Thickeners
In CD, it may be prudent to reduce intake of processed foods that contain carrageenan, carboxymethylcellulose, and polysorbate-80.
(VL)In UC, it may be prudent to reduce intake of processed foods that contain carrageenan, carboxymethylcellulose, and polysorbate-80.
(VL)Nanoparticles and Sulfites
In CD, it may be prudent to reduce exposure to processed foods containing titanium dioxide and sulfites.
(L)In UC, it may be prudent to reduce exposure to processed foods containing titanium dioxide and sulfites.
(VL)Recommendation Grading
Overview
Title
Dietary Guidance for Patients with Inflammatory Bowel Disease
Authoring Organization
International Organization for the Study of Inflammatory Bowel Diseases
Publication Month/Year
February 14, 2020
Last Updated Month/Year
February 5, 2024
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Inclusion Criteria
Adolescent, Adult, Child, Infant, Older adult
Health Care Settings
Ambulatory, Hospital, Operating and recovery room, Outpatient
Intended Users
Dietician nutritionist, nurse, nurse practitioner, physician, physician assistant
Scope
Counseling, Assessment and screening, Diagnosis, Management, Treatment
Diseases/Conditions (MeSH)
D003424 - Crohn Disease, D043183 - Irritable Bowel Syndrome
Keywords
irritable bowel syndrome (IBS), ulcerative colitis, Crohn's disease
Source Citation
Levine, A., Rhodes, J. M., Lindsay, J. O., Abreu, M. T., Kamm, M. A., Gibson, P. R., … Lewis, J. D. (2020). Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2020.01.046